TWAICE
2.9.2021 15:02:11 CEST | Business Wire | Press release
Battery analytics software expert TWAICE today announced a collaboration with Analog Devices, Inc., a global semiconductor and system solutions company, to tackle the challenges of battery lifecycle optimization. The combination of Analog Devices’ sensor technology and wireless connectivity with TWAICE’s battery analytics software will benefit customers in the mobility and energy sectors. The alliance will be instrumental in significantly reducing warranty risks and recalls, optimizing battery life, and enhancing battery value.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210902005016/en/
Analog Devices is a global leader in battery management systems, and high-performance analog, mixed-signal, and digital signal processing solutions. The collaboration with the software company TWAICE, whose platform provides end-to-end battery analytics solutions, will enable the optimization of the entire battery lifecycle.
Mobility is at an inflection point, with electrified powertrains replacing combustion engines. Battery reliability and economics are critical in the widespread deployment of renewable energies and electric vehicles. Battery performance and lifespan play a key role in the sustainability of solutions they are deployed in, yet the assessment thereof is often challenging. “Precision data combined with advanced predictive battery analytics will shed light into the darkness, which is crucial in unlocking as yet undiscovered potential along the entire value chain," said Dr. Stephan Rohr, Co-CEO of TWAICE.
“The battery is the energy source for every electric vehicle, and it is also a valuable asset,” said Patrick Morgan, Vice President of Automotive at Analog Devices. “Together with TWAICE, we are delivering innovative holistic solutions across battery lifetimes that create significant value for our customers and support a circular economy.”
The goal of the collaboration is to provide a holistic lifecycle solution for automakers with integrated hardware and software. Accurate battery measurements provided through a wireless battery management system form the basis. Analog Devices’ sensor technology provides data, and a quality thereof previously unavailable. TWAICE can generate crucial insights into the battery performance desired by companies around the globe. The resulting forecasts enable qualified statements at any point in the battery lifecycle regarding its value and usability.
About Analog Devices Inc.
Analog Devices (ADI), headquartered in Norwood, Massachusetts, is a global leader in the design, manufacture and marketing of a broad portfolio of high-performance analog, mixed-signal, DSP circuits and microchips used in virtually all types of electronic devices. With over 55 years of market experience, 16,000 employees worldwide today, over 4,700 patents and 125,000 customers in instrumentation, automation, communications, healthcare, automotive and numerous other industries, Analog Devices is dedicated to solving technical challenges associated with signal processing in electronic devices. More at www.analog.com .
About TWAICE
TWAICE provides predictive analytics software that optimizes both the development and operation of lithium-ion batteries. As the leading provider of battery analytics software to global electric vehicle and energy companies, TWAICE increases the longevity, efficiency and sustainability of products that drive tomorrow's economy. More at www.twaice.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210902005016/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom